Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

2768445-19-6Upadacitinib Trifluoroacetamide Impurity

● Auf Lager

Katalog-Nr.::	VE0027858
CAS-Nr.::	2768445-19-6
Summenformel::	C23H22F3N5O3S
Molare Masse::	505.51 g/mol

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 2768445-19-6

Parent drug

Upadacitinib

IUPAC-Name

1-((3S,4R)-3-ethyl-4-(3-tosyl-3H-imidazo[1,2-a]pyrrolo [2,3-e]pyrazin-8-yl) pyrrolidin-1- yl)-2,2,2-trifluoroethanone

Pharmacopeial Synonyms

N/A

Synonyme

N/A

SMILES

FC(F)(F)C(N1C[C@@H](CC)[C@@H](C2=CN=C3C=NC(N(S(=O)(C4=CC=C(C)C=C4)=O)C=C5)=C5N32)C1)=O

InChI

InChI=1S/C23H22F3N5O3S/c1-3-15-12-29(22(32)23(24,25)26)13-17(15)19-10-27-20-11-28-21-18(31(19)20)8-9-30(21)35(33,34)16-6-4-14(2)5-7-16/h4-11,15,17H,3,12-13H2,1-2H3/t15-,17+/m1/s1

Beschreibung

Upadacitinib Trifluoroacetamide Impurity (CAS 2768445-19-6) is a process-related byproduct formed during trifluoroacetylation steps in Upadacitinib synthesis, requiring targeted analytical characterization and control. This impurity exhibits distinct mass and 19F NMR signatures enabling detection by LC-MS and fluorine-sensitive NMR methods, while HPLC with appropriate reference standards supports quantitation. Relevant quality considerations include establishment of identification thresholds, qualification limits per ICH Q3A/B, forced degradation studies to assess stability, and implementation of purification or process adjustments to minimize carryover. Accurate profiling of this impurity is essential for regulatory submissions and consistent drug substance quality.